Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.

Masayuki TakedaTakayuki TakahamaKazuko SakaiShigeki ShimizuSatomi WatanabeHisato KawakamiKaoru TanakaChihiro SatoHidetoshi HayashiYoshikane NonagaseKimio YonesakaNaoki TakegawaTatsuya OkunoTakeshi YoshidaSoichi FumitaShinichiro SuzukiKoji HarataniKazumasa SaigohAkihiko ItoTetsuya MitsudomiHisashi HandaKazuya FukuokaKazuhiko NakagawaKazuto Nishio

Published in: The oncologist (2021)

This prospective cohort study was initiated to investigate the feasibility and utility of clinical application of FoundationOne CDx. A total of 181 samples were processed for genomic testing between September 2018 and June 2019, with data being successfully obtained for 175 of these samples, yielding a success rate of 96.7%, and 24 individuals (14%) received matched targeted therapy.

Keyphrases

decision making
high throughput
copy number
big data
dna methylation